Matthew Wallace

Immune checkpoint therapy—current perspectives and future directions

Blocking PD-L1–PD-1 improves senescence surveillance and ageing phenotypes

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models

Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis